Barclays Maintains Overweight on Intuitive Surgical, Lowers Price Target to $651

Benzinga Newsdesk www.benzinga.com Negative 91.7%

Neg 91.7% Neu 0% Pos 0%

Barclays analyst Matt Miksic maintains Intuitive Surgical (NASDAQ:ISRG) with a Overweight and lowers the price target from $712 to $651.